About
Description
Research centre for cancer, neurosciences and translational medicine The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center established in 2004. Its stakeholders are Bellvitge University Hospital and Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology, University of Barcelona and the town council of L’Hospitalet de Llobregat. IDIBELL is located in L’Hospitalet de Llobregat, south of Barcelona. It is a member of the Campus of International Excellence of the University of Barcelona HUBc and part of the CERCA institution of the Generalitat of Catalonia. In 2009, it became one of the first five Spanish research centers accredited as a health research institute by the Carlos III Institute of Health. A key aspect of research in IDIBELL is its proximity to the patient. Because of its location and the healthcare activity that many of its researchers carry out, IDIBELL research groups can identify which problems are really priority and which solutions are effective in daily clinical practice.
Services
Life Cycle Assessment (LCA)
Analyze the lifecycles of products and services with regard to their environmental impacts.
Viral Vector Production
Produce viral vectors for gene therapy and vaccine development.
Data Visualization
Visualize data collected from clinical trials and/or clinical research.
Emerging Market Opportunities
Analyze risks and opportunities in new markets for patient access to new treatments.
Adverse Event Reporting
Monitor and report adverse events related to drug products in clinical trials.
Organization members
Amanda Lee
Communications Director
William Kim
Data Analyst
Laura Martinez
Clinical Trials Coordinator
Michael Brown
Executive Director
Robert Garcia
Fundraising Director
Emily Davis
Research Scientist